13F Holdings
中文EN

RYTM RHYTHM PHARMACEUTICALS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1649904 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY61.0%
TTM net income YoY-0.8%
TTM EPS YoY6.1%
Revenue 3-yr CAGR65.5%
Net income 3-yr CAGR—

Margins

Gross margin88.2%
Operating margin-66.7%
Net margin-69.0%
FCF margin—
EBITDA margin—

Returns

ROE-163.7%
ROA-40.8%
ROIC (approx.)-83.0%
Asset turnover0.59x

Leverage & solvency

Liabilities / assets54.5%
Debt / equity1.17x
Current ratio2.78x
Interest coverage-10.27x

Cash quality & payout

Operating cash flow / net income0.42x
Accruals ratio-23.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$189.76M$130.13M$77.43M$23.64M$3.15M
Cost of revenue$19.49M$13.37M$9.30M$2.13M$599,000
Gross profit$170.26M$116.76M$68.13M$21.50M$2.56M
R&D expense$167.34M$237.96M$134.95M$108.63M$104.13M
SG&A expense$194.94M$144.30M$117.53M$92.03M$68.49M
Operating income-$192.02M-$265.50M-$184.36M-$179.16M-$170.06M
Interest expense$20.58M$20.60M$13.89M$5.20M—
Pretax income-$196.04M-$260.26M-$184.11M-$181.12M-$69.61M
Income tax$497,000$346,000$564,000——
Net income-$196.54M-$260.60M-$184.68M-$181.12M-$69.61M
EBITDA-$191.52M-$264.80M-$183.46M-$178.26M-$169.24M
EPS (basic)-3.11-4.34-3.20-3.47-1.40
EPS (diluted)-3.11-4.34-3.20-3.47-1.40
Weighted avg. shares (diluted)64.98M61.00M57.67M52.12M49.60M
Balance sheet
Cash & equivalents$54.30M$89.14M$60.08M$127.68M$59.25M
Short-term investments$334.65M$231.43M$215.76M$205.61M$235.61M
Receivables$26.08M$18.51M$14.87M$6.22M$1.02M
Inventory$25.75M$18.74M$8.62M$2.92M$111,000
Current assets$466.92M$374.20M$308.27M$354.24M$308.39M
PP&E, net$1.10M$632,000$1.34M$2.20M$2.81M
Intangibles$5.32M$6.17M$7.03M$7.88M$4.66M
Total assets$480.20M$392.27M$332.75M$382.48M$329.52M
Current liabilities$105.94M$115.52M$55.20M$39.81M$43.43M
Short-term debt$7.30M$1.54M———
Long-term debt$100.89M$108.27M$106.14M——
Total debt$108.18M$109.81M$106.14M——
Total liabilities$210.17M$227.72M$162.99M$118.22M$45.37M
Shareholders' equity$139.07M$21.73M$169.76M$264.26M$284.15M
Net debt$53.88M$20.67M$46.06M——
Shares outstanding67.21M62.39M59.43M56.61M50.28M
Cash flow statement
Operating cash flow-$115.67M-$113.88M-$136.16M-$173.43M-$146.00M
Capital expenditure$953,000$0$47,000$281,000$434,000
Free cash flow-$116.63M-$113.88M-$136.20M-$173.71M-$146.44M
Investing cash flow-$137.15M-$48.17M-$5.67M$28.03M-$62.16M
Financing cash flow$217.96M$191.24M$74.37M$213.83M$166.48M
Depreciation & amortization$500,000$700,000$900,000$896,000$816,000
Stock-based compensation$66.82M$39.68M$32.55M$19.83M$20.80M

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.